Georgia Beasley

Positions:

Assistant Professor of Surgery

Surgical Oncology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

B.A. 2001

Duke University

M.D. 2008

Duke University School of Medicine

M.H.S. 2012

Duke University

General Surgery Resident, Surgery

Duke University

Surgical Oncology Fellow, Surgery

Ohio State University

Grants:

A Phase I trial of PVSRIPO for Patients with Unresectable Melanoma

Administered By
Duke Cancer Institute
Awarded By
Istari Oncology
Role
Principal Investigator
Start Date
End Date

A Randomized, Controlled, Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients with Hepatic-Dominant Ocular Melanoma

Administered By
Duke Cancer Institute
Awarded By
Delcath Systems, Inc.
Role
Principal Investigator
Start Date
End Date

Comprehensive immunologic profiling of the sentinel node to optimize care for patients with melanoma

Awarded By
Society of Surgical Oncology
Role
Principal Investigator
Start Date
End Date

OMS-I103 / PICSES

Administered By
Duke Cancer Institute
Awarded By
OncoSec Medical
Role
Principal Investigator
Start Date
End Date

Publications:

Injectable Therapies for Regional Melanoma.

Patients with unresectable cutaneous, subcutaneous, or nodal melanoma metastases are often candidates for injectable therapies, which are attractive for ease of intralesional delivery to superficial metastases and limited systemic toxicity profiles. Injectable or intralesional therapies can be part of multifaceted treatment strategies to kill tumor directly or to alter the tumor so as to make it more sensitive to systemic therapy. Talimogene laherparepvec is the only Food and Drug Administration-approved injectable therapy currently in wide clinical use in the United States, although ongoing trials are evaluating novel intralesional agents as well as combinations with systemic therapies, particularly checkpoint inhibitors.
Authors
Farrow, NE; Leddy, M; Landa, K; Beasley, GM
MLA Citation
Farrow, Norma E., et al. “Injectable Therapies for Regional Melanoma.Surg Oncol Clin N Am, vol. 29, no. 3, July 2020, pp. 433–44. Pubmed, doi:10.1016/j.soc.2020.02.008.
URI
https://scholars.duke.edu/individual/pub1447455
PMID
32482318
Source
pubmed
Published In
Surg Oncol Clin N Am
Volume
29
Published Date
Start Page
433
End Page
444
DOI
10.1016/j.soc.2020.02.008

Acral Melanomas of the Sole May Have Worse Prognosis Compared with Other Sites of Acral Melanoma.

Authors
MLA Citation
Beasley, Georgia M. “Acral Melanomas of the Sole May Have Worse Prognosis Compared with Other Sites of Acral Melanoma.Ann Surg Oncol, vol. 27, no. 9, Sept. 2020, pp. 3121–22. Pubmed, doi:10.1245/s10434-020-08460-3.
URI
https://scholars.duke.edu/individual/pub1440463
PMID
32306236
Source
pubmed
Published In
Annals of Surgical Oncology
Volume
27
Published Date
Start Page
3121
End Page
3122
DOI
10.1245/s10434-020-08460-3

Factors predicting toxicity and response following isolated limb infusion for melanoma: An international multi-centre study.

INTRODUCTION: Isolated limb infusion (ILI) is a minimally-invasive procedure for delivering high-dose regional chemotherapy to treat melanoma in-transit metastases confined to a limb. The aim of this international multi-centre study was to identify predictive factors for toxicity and response. METHODS: Data of 687 patients who underwent a first ILI for melanoma in-transit metastases confined to the limb between 1992 and 2018 were collected at five Australian and four US tertiary referral centres. RESULTS: After ILI, predictive factors for increased limb toxicity (Wieberdink grade III/IV limb toxicity, n = 192, 27.9%) were: female gender, younger age, procedures performed before 2005, lower limb procedures, higher melphalan dose, longer drug circulation and ischemia times, and increased tissue hypoxia. No patient experienced grade V toxicity (necessitating amputation). A complete response (n = 199, 28.9%) was associated with a lower stage of disease, lower burden of disease (BOD) and thinner Breslow thickness of the primary melanoma. Additionally, an overall response (combined complete and partial response, n = 441, 64.1%) was associated with female gender, Australian centres, procedures performed before 2005, lower limb procedures and lower actinomycin-D doses. On multivariate analysis, higher melphalan dose remained a predictive factor for toxicity, while lower stage of disease and lower BOD remained predictive factors for overall response. CONCLUSION: ILI is safe and effective to treat melanoma in-transit metastases. Predictive factors for toxicity and response identified in this study will allow improved patient selection and optimization of intra-operative parameters to increase response rates, while keeping toxicity low.
Authors
Kenyon-Smith, TJ; Kroon, HM; Miura, JT; Teras, J; Beasley, GM; Mullen, D; Farrow, NE; Mosca, PJ; Lowe, MC; Farley, CR; Potdar, A; Daou, H; Sun, J; Farma, JM; Henderson, MA; Speakman, D; Serpell, J; Delman, KA; Smithers, BM; Barbour, A; Coventry, BJ; Tyler, DS; Zager, JS; Thompson, JF
MLA Citation
Kenyon-Smith, Timothy J., et al. “Factors predicting toxicity and response following isolated limb infusion for melanoma: An international multi-centre study.Eur J Surg Oncol, 2020. Pubmed, doi:10.1016/j.ejso.2020.06.040.
URI
https://scholars.duke.edu/individual/pub1435969
PMID
32739218
Source
pubmed
Published In
Eur J Surg Oncol
Published Date
DOI
10.1016/j.ejso.2020.06.040

Mind the gap: Gendered publication trends in oncology.

BACKGROUND:Investigating scientific publication trends in the field of oncology may highlight opportunities for improved representation, mentorship, collaboration, and advancement for women. METHODS:We conducted a bibliometric analysis of Annals of Surgical Oncology; Cancer; International Journal of Radiation Oncology, Biology, Physics (IJROBP); JAMA Oncology; and Journal of Clinical Oncology in 1990, 2000, 2010, and 2017. Full name and degree credentials per author role (ie, first or senior author), article type, publication year, and citation metrics were collected. First names were used to identify author gender. RESULTS:Across 9189 articles, female representation rose between 1990 and 2017 (first authors: 17.7% in 1990, 36.6% in 2017; senior authors: 11.7% in 1990, 28.5% in 2017). For the 50 most cited articles per year, women comprised a smaller percent of first (26.5%) and senior (19.9%) authors. The average citation count was higher for male first (44.8 per article) and senior (47.1) authors compared to female first (39.7) and senior (44.1) authors. With male senior authors, the first author was more likely male (71.4% male; 25.0% female); with female senior authors, first authors were 50.2% male and 47.6% female. IJROBP had the lowest total female representation among first (25.1%) and senior (16.7%) authors. Women had more MDs with Masters degrees, whereas men held more MDs only and more MDs with PhDs. CONCLUSION:Despite positive trends, substantial gendered differences in oncology publications persist. Fostering more women in oncology research will benefit female representation at many levels of academia and improve productivity, collaboration, and recruitment, especially in technical fields such as radiation and surgical oncology.
Authors
Dalal, NH; Chino, F; Williamson, H; Beasley, GM; Salama, AKS; Palta, M
MLA Citation
Dalal, Nicole H., et al. “Mind the gap: Gendered publication trends in oncology.Cancer, vol. 126, no. 12, June 2020, pp. 2859–65. Epmc, doi:10.1002/cncr.32818.
URI
https://scholars.duke.edu/individual/pub1435855
PMID
32212334
Source
epmc
Published In
Cancer
Volume
126
Published Date
Start Page
2859
End Page
2865
DOI
10.1002/cncr.32818

ASO Author Reflections: Adjuvant Therapy is Effective for Melanoma Patients with Positive Sentinel Lymph Node Biopsy Who Forgo Completion Lymphadenectomy.

Authors
Farrow, NE; Beasley, GM
MLA Citation
Farrow, Norma E., and Georgia M. Beasley. “ASO Author Reflections: Adjuvant Therapy is Effective for Melanoma Patients with Positive Sentinel Lymph Node Biopsy Who Forgo Completion Lymphadenectomy.Ann Surg Oncol, May 2020. Pubmed, doi:10.1245/s10434-020-08561-z.
URI
https://scholars.duke.edu/individual/pub1442267
PMID
32409964
Source
pubmed
Published In
Annals of Surgical Oncology
Published Date
DOI
10.1245/s10434-020-08561-z